-
Lambda Protein Phosphatase for BMAL1 Studies
2026-09-08
Use Lambda Protein Phosphatase to distinguish phosphorylation-dependent BMAL1 behavior from antibody artifacts, protein abundance, and condensate-buffer effects. This practical workflow combines paired dephosphorylation controls with phospho-antibody validation, phase-separation assays, and phosphorylation site validation.
-
O-GlcNAc–HUWE1–TfR1 Axis in Preeclampsia
2026-09-07
This study identifies an O-GlcNAc–HUWE1–TfR1 pathway that links protein O-GlcNAc modification to iron uptake, ferroptosis, and trophoblast syncytialization in preeclampsia. Its findings suggest that stabilizing O-GlcNAcylated HUWE1 promotes TfR1 ubiquitination and degradation, thereby limiting iron-dependent trophoblast injury and improving pregnancy outcomes in mice.
-
Ataxin-3, CFTR, and Microglial Inflammation
2026-09-07
The reference study identifies an Ataxin-3–K63 ubiquitin chain–CFTR pathway that links polyglutamine-expanded Ataxin-3 to accelerated CFTR turnover and pro-inflammatory microglial activation. Its findings provide a mechanistic framework for studying SCA3-associated neuroinflammation while highlighting the importance of preserving protein abundance, ubiquitination, and phosphorylation-sensitive signals during biochemical analysis.
-
PAD4-IN-2 TFA: Tumor-Targeted Workflows
2026-09-05
PAD4-IN-2 TFA, also known as Compound 5i TFA, combines PAD4 inhibition with meta-phenylboronic acid-mediated tumor targeting for studies of NET biology, metastasis, and immune remodeling. This practical guide connects dose-response, uptake, H3cit, migration, and in vivo workflows while emphasizing controls that distinguish tumor-cell effects from neutrophil-mediated mechanisms.
-
Tolazoline for Islet and Airway Pharmacology
2026-09-04
Tolazoline is an α2-adrenergic receptor antagonist that also provides a useful functional probe of ATP-sensitive potassium channels in β-cell assays. This article translates the evidence into practical workflows for islet function research and in vitro airway smooth muscle studies, with controls that help distinguish receptor-mediated effects from ion-channel activity.
-
LC–MS/MS Traces GS-441524 Prodrug Activation
2026-09-04
A January 2026 Microchemical Journal study established an LC–MS/MS strategy to follow conversion of the novel GS-441524 prodrug NGP-1 into GS441 in gastric fluid, blood, liver microsomes, and liver-injury model rats. The work provides a matrix-resolved framework for interpreting prodrug stability, hepatic metabolism, systemic hydrolysis, and GS-441524 pharmacokinetics during preclinical development.
-
XAV-939: From Wnt Control to Translational Insight
2026-09-03
XAV-939, also known as NVP-XAV939, is more than a Wnt pathway probe. By inhibiting TNKS1/2, stabilizing axin, and influencing the Hippo-YAP network, it offers translational researchers a mechanistic framework for connecting pathway state with cancer, fibrosis, and bone biology.
-
Dibutyryl-cAMP, Sodium Salt in Astrocyte Reprogramming
2026-09-03
Explore how Dibutyryl-cAMP, sodium salt can strengthen assay design for astrocyte-to-motoneuron reprogramming without being mistaken for a replacement for transcription-factor cocktails. This evidence-led guide connects DBcAMP sodium salt, stage-specific readouts, and cAMP signaling pathway research.
-
Cell Lysis Buffer for WB and IP in Cancer Biology
2026-09-02
Mechanistic studies of cancer-associated fibroblasts increasingly depend on preserving native protein complexes, phosphorylation states, and tissue-specific signaling context. This thought-leadership article examines how Cell lysis buffer for WB and IP can support investigation of the ANGPTL4-IQGAP1 axis, mitochondrial metabolism, and chemoresistance in prostate cancer while offering practical guidance for Western blot, immunoprecipitation, and translational workflow design.
-
1-Myristoylglycerophosphocholine: Assay Logic
2026-09-02
1-myristoylglycerophosphocholine, also called 14:0 Lyso-PC, is more than a lipid reagent: it is a defined perturbation for separating lysophospholipid correlation from causality. This guide connects lipidomics, fibroblast activation, and smooth muscle assays while emphasizing species identity, controls, and interpretation.
-
PBS Liposomes for Reliable Macrophage Controls
2026-09-01
PBS Liposomes provide a non-depleting, phagocytosis-compatible comparator for separating clodronate-specific macrophage loss from effects caused by liposome delivery. This workflow-focused guide explains how to pair phosphate-buffered saline liposomes with clodronate liposomes, standardize handling, and troubleshoot ambiguous in vivo results.
-
TRPM3 Regulation by Neurosteroids and Primidone
2026-09-01
Yin et al. combine cryo-electron microscopy, electrophysiology, molecular dynamics, and mass spectrometry to define how pregnenolone sulfate, CIM0216, and primidone regulate TRPM3. The resulting ligand-binding and gating framework connects TRPM3 pharmacology with nociception, neurodevelopmental disease, and structure-guided inhibitor design.
-
OSMI-1 Workflow for O-GlcNAcylation Research
2026-08-31
OSMI-1 provides a cell-permeable way to test how OGT-dependent protein modification shapes trophoblast stress, iron handling, and ferroptosis. This practical guide combines dose-finding, Nup62-based target engagement, HUWE1–TfR1 pathway analysis, and troubleshooting for cleaner mechanistic conclusions.
-
CKI 7 dihydrochloride: CK1 Workflows
2026-08-31
Build cleaner CK1 perturbation experiments with CKI 7 dihydrochloride, from concentration-controlled cell assays to pathway-specific validation. The workflow also shows how to use the compound alongside, rather than as a substitute for, mechanistic studies of phosphorylation, ubiquitination, and cancer-cell invasion.
-
Okadaic acid (A4540): PP1/PP2A Workflow Guide
2026-08-30
Okadaic acid (A4540) provides controlled inhibition of PP2A at low nanomolar potency and PP1 at higher concentrations, helping researchers connect phosphatase activity with phosphorylation-dependent signaling and apoptosis endpoints. It is appropriate for defined biochemical and cell-based experiments, but should not be treated as a broad phosphatase inhibitor or used without vehicle, concentration, and assay-specific controls.